- Home
- ROIV vs EHC Comparison
ROIV vs EHC Comparison
Compare ROIV & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- EHC
- Stock Information
- Founded
- ROIV 2014
- EHC 1983
- Country
- ROIV United Kingdom
- EHC United States
- Employees
- ROIV N/A
- EHC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- EHC Hospital/Nursing Management
- Sector
- ROIV Health Care
- EHC Health Care
- Exchange
- ROIV Nasdaq
- EHC Nasdaq
- Market Cap
- ROIV 8.4B
- EHC 9.7B
- IPO Year
- ROIV N/A
- EHC 1986
- Fundamental
- Price
- ROIV $10.38
- EHC $100.69
- Analyst Decision
- ROIV Strong Buy
- EHC Strong Buy
- Analyst Count
- ROIV 6
- EHC 8
- Target Price
- ROIV $17.10
- EHC $107.38
- AVG Volume (30 Days)
- ROIV 6.9M
- EHC 716.9K
- Earning Date
- ROIV 02-10-2025
- EHC 04-23-2025
- Dividend Yield
- ROIV N/A
- EHC 0.68%
- EPS Growth
- ROIV N/A
- EHC 28.32
- EPS
- ROIV N/A
- EHC 4.46
- Revenue
- ROIV $122,585,000.00
- EHC $5,373,200,000.00
- Revenue This Year
- ROIV N/A
- EHC $10.10
- Revenue Next Year
- ROIV N/A
- EHC $8.67
- P/E Ratio
- ROIV N/A
- EHC $22.47
- Revenue Growth
- ROIV 140.04
- EHC 11.91
- 52 Week Low
- ROIV $9.96
- EHC $78.53
- 52 Week High
- ROIV $13.06
- EHC $104.55
- Technical
- Relative Strength Index (RSI)
- ROIV 42.16
- EHC 55.93
- Support Level
- ROIV $10.63
- EHC $99.82
- Resistance Level
- ROIV $11.42
- EHC $101.96
- Average True Range (ATR)
- ROIV 0.36
- EHC 2.20
- MACD
- ROIV -0.02
- EHC 0.38
- Stochastic Oscillator
- ROIV 7.59
- EHC 86.53
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.